Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 16/20 | 1.00 |
| ▸ | BRD4 | O60885 | 8/20 | 1.00 |
| ▸ | DCLK1 | O15075 | 14/20 | 0.83 |
| ▸ | MAPK7 | Q13164 | 12/20 | 0.83 |
| ▸ | GAK | O14976 | 1/20 | 0.56 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.56 |
| ▸ | TNK1 | Q13470 | 1/20 | 0.56 |
| ▸ | DCLK2 | Q8N568 | 1/20 | 0.56 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20094404 | 0.91 | LRRK2 (1.00) | LRRK2BRD4DCLK1MAPK7GAK | |
| SCHEMBL31092850 | 0.87 | LRRK2 (1.00) | LRRK2BRD4DCLK1MAPK7GAK | |
| SCHEMBL20094173 | 0.87 | LRRK2 (1.00) | LRRK2BRD4DCLK1MAPK7GAK | |
| SCHEMBL20094174 | 0.84 | LRRK2 (1.00) | LRRK2BRD4DCLK1MAPK7GAK | |
| SCHEMBL31092828 | 0.82 | LRRK2 (1.00) | LRRK2BRD4DCLK1MAPK7GAK | |
| SCHEMBL20094180 | 0.82 | LRRK2 (1.00) | LRRK2BRD4DCLK1MAPK7GAK | |
| SCHEMBL31092837 | 0.82 | LRRK2 (1.00) | LRRK2BRD4DCLK1MAPK7GAK | |
| SCHEMBL20094195 | 0.77 | BRD4 (1.00) | LRRK2BRD4DCLK1MAPK7NUAK1 | |
| SCHEMBL17059944 | 0.77 | LRRK2 (0.72) | LRRK2BRD4DCLK1MAPK7GAK | |
| SCHEMBL17469567 | 0.76 | DCLK1 (1.00) | LRRK2BRD4DCLK1MAPK7NUAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3528814-B1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DCLK1/2-MEDIATED DISORDERS | DANA FARBER CANCER INST INC (US) | 2024-08-14 | — | — | EP | disclosed |
| US-11028089-B2 | Pyrimido-diazepinone kinase scaffold compounds and methods of treating DCLK1/2-mediated disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-06-08 | — | — | US | disclosed |
| US-11028089-B2 | Pyrimido-diazepinone kinase scaffold compounds and methods of treating DCLK1/2-mediated disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-06-08 | — | — | US | disclosed |
| US-20190315753-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DCLK1/2-MEDIATED DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-10-17 | — | — | US | disclosed |
| US-20190315753-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DCLK1/2-MEDIATED DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-10-17 | — | — | US | disclosed |
| WO-2018075608-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DCLK1/2-MEDIATED DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190315753-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DCLK1/2-MEDIATED DISORDERS | CAMK1, CAMKK2, DCLK2 | LRRK2 162/4885BRD4 479/4885DCLK1 7/4885 |
| US-11028089-B2 | Pyrimido-diazepinone kinase scaffold compounds and methods of treating DCLK1/2-mediated disorders | CAMK1, CAMKK2, DCLK2 | LRRK2 162/4885BRD4 479/4885DCLK1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.